Phase 1 clinical trial evaluating whether probiotic supplementation prevents chemotherapy-induced diarrhoea and other intestinal adverse effects in cancer patients.
The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea/neutropenia: an exploratory end-point pilot study
Medlab Clinical
30 participants
Feb 28, 2019
Interventional
Conditions
Summary
The purpose of this study is to test the safety and tolerability of the MultiBiotic probiotic formulation before starting chemotherapy and until the end of treatment. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with cancer and have not yet commenced chemotherapy. Study details Patients who decide to take part in this trial will be given probiotic (friendly gut bacteria) capsules to be taken daily before and during the duration of the chemotherapy. The probiotic has been developed to support gastrointestinal health. It contains three species of Lactobacilli, three species of Bifidobacterium and one species of Streptococcus bacteria. Participants will be asked about their general wellbeing at the beginning and at the end of the study. They will also be asked to keep a record of intestinal symptoms. A stool and a blood test will be required at beginning and at the end of the study. Chemotherapy is associated with mucositis manifesting as pain, inflammation, diarrhoea, weight loss, and infection. It is hoped that this research will help improve the general wellbeing of patients during chemotherapy.
Eligibility
Inclusion Criteria5
- Adult patient diagnosed with cancer and who are chemotherapy naïve or about to commence a new chemotherapy regimen due to disease progression
- Life expectancy more than 12 months
- Absence of any psychological, familial, sociological or geographical conditions, which could potentially hamper compliance with the study protocol and follow-up schedule;
- Willingness to comply with the study.
- Signed and written informed consent
Exclusion Criteria7
- Active infection treated by antibiotic therapy
- Ileostomy
- Hypersensitivity to study drug
- Any concurrent malignancy other than non-melanoma skin cancer, no other cancer in past 5 years.
- Serious concomitant systemic disorders or diseases incompatible with the study
- Patient has a history of primary psychological disorder
- Illicit drug use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: MultiBiotic probiotic formulation containing per capsule: Lactobacillus rhamnosus (Med 26) 9 billion CFU Lactobacillus acidophilus (Med 27) 3.75 billion CFU Lactobacillus plantarum (Med 25) 1.575 billion CFU Bifidobacterium animalis spp. lactis (Med 13) 3 billion CFU Bifidobacterium breve (Med 12) 1.75 billion CFU Bifidobacterium bifidum (Med 11) 500 million CFU Streptococcus thermophilus (Med 51) 1.5 billion CFU Total 21.075 Billion CFU* / 1 capsule Dosage: 2 capsules twice daily. Mode of administration: oral Duration of intervention: 12 weeks Monitoring: Drug bottles returned (empty or not) to trial investigator.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618000927224